Name tweak could boost GLP-1 access for one in eight women suffering PMOS
A global effort has led to the renaming of Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), potentially improving access to GLP-1 weight loss medications for affected women. This change aims to enhance understanding and treatment of the condition, which affects 1 in 8 women and is linked to various metabolic issues. Experts believe that while FDA approval for GLP-1 medications specifically for PMOS may take time, women may still access these treatments through insurance for related conditions.
- ▪The name change from PCOS to PMOS is intended to improve diagnosis and treatment options for women.
- ▪PMOS is the leading cause of infertility in the United States and is associated with various symptoms including weight issues and hormonal imbalances.
- ▪GLP-1 weight loss medications have shown promise in stabilizing insulin levels in PMOS patients.
Opening excerpt (first ~120 words) tap to expand
Millions of women could soon have greater access to GLP-1 weight loss medications following the global effort to change the name of a hormonal condition that affects 1 in 8 women globally. The condition, formerly known as Polycystic Ovarian Syndrome, or PCOS, recently underwent a name change following a years-long international effort, led by the Endocrine Society and women’s health researchers worldwide, to update how clinicians care for women struggling with the disease. Recommended Stories Congo faces underlying challenges in battle to overcome Ebola: ‘You gotta have safety’ UNICEF’s first shipment of supplies arrives in Congo for Ebola outbreak RFK Jr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
